GET DAILY SIGNALSAxon Enterprise (AXON) vs Codexis (CDXS): -43% vs +21% YTD in Contrasting Growth Stories
Key Takeaways
- Axon Enterprise (AXON) is a large-cap public safety technology leader (market capitalization near $34.6 billion) with profitable, recurring revenue growth, while Codexis (CDXS) is a micro-cap biotechnology firm (market capitalization near $140 million) still investing ahead of scaled commercial revenue.
- Despite roughly 30%+ revenue growth, AXON has been under pressure recently — down about 43% over the past year — as a premium valuation reset amid the broader software sell-off.
- CDXS trades near $1.28, well below its 52-week high of roughly $2.98, but is up about 21% year-to-date on progress in its ECO Synthesis platform and an extended cash runway into 2028.
- The two business models differ sharply: AXON generates profits and recurring software revenue, while CDXS remains unprofitable and guides 2026 revenue to only $72–76 million.
- Risk profiles diverge: AXON faces valuation and government-budget risk, while CDXS carries execution, dilution, and adoption risk with a high beta (about 2.55, indicating amplified volatility versus the broader market).
- For further detail on each name, explore AXON Major News and AXON Today's Price Move, as well as CDXS Major News and CDXS Today's Price Move.
- To see how automated strategies are positioning across the market, explore the Trending AI Robots page.
Introduction
This comparison places two very different publicly traded companies side by side: Axon Enterprise, a dominant provider of TASER devices, body cameras, and public safety software, and Codexis, a developer of engineered enzymes and a manufacturing platform for RNA-based therapeutics. Investors weighing a large-cap, hardware-plus-software growth story against a speculative, pre-profit biotechnology platform may find the contrast instructive. The two names differ sharply in scale, profitability, momentum, and risk, making them useful reference points for understanding how market positioning and sector exposure shape relative performance in the current environment. I also checked sector peers using Tickeron’s AI Screener to confirm the broader context.
AXON Overview and Recent Performance
Axon Enterprise, based in Scottsdale, Arizona, sells connected public safety technology, including TASER energy devices, body-worn and in-car cameras, drones, and cloud software for digital evidence and records management. Its recurring software layer is a central growth engine: annual recurring revenue has reached about $1.6 billion, with net revenue retention around 126% and future contracted bookings near $15.1 billion.
Recent market activity has been volatile. After reaching record highs in mid-2025, AXON shares fell sharply through late 2025 and early 2026, caught up in a broad sell-off of software names even as fundamentals stayed strong. Revenue rose roughly 39% year over year in its latest quarter, and the company recently unveiled its Body 5 camera with enhanced AI processing. Analysts broadly retain a "Buy" consensus rating, though several have trimmed price targets. The shares now trade near $426, reflecting a reset of a valuation that previously carried a triple-digit forward price-to-earnings (P/E) ratio. From what I see, the pullback creates an interesting entry point for long-term holders.
CDXS Overview and Recent Performance
Codexis, headquartered in Redwood City, California, uses its proprietary CodeEvolver platform to engineer enzymes for pharmaceutical manufacturing. The company operates a stable small-molecule biocatalysis business alongside its ECO Synthesis platform, an enzymatic route intended to scale the manufacture of RNA interference (RNAi) therapies — treatments that silence specific genes — such as siRNA (small interfering RNA) medicines.
In recent months, CDXS has made progress on its GMP (Good Manufacturing Practice) manufacturing facility and expanded engagement with contract development and manufacturing organizations (CDMOs) and the FDA's Emerging Technologies team. Still, revenue remains small: full-year 2026 guidance is $72–76 million, and the company reported a net loss of about $12 million in its latest quarter. Cash of roughly $54.9 million is expected to fund operations through 2028. The stock trades near $1.28, roughly 50% above its 52-week low but well below recent highs, reflecting both optimism about the platform and lingering dilution and execution concerns. I’m watching this closely as clinical milestones approach.
Head-to-Head Comparison
The core contrast is scale and maturity. AXON is a profitable, cash-generating operator with a hardware-to-software flywheel and entrenched relationships with public safety agencies; its principal challenge is valuation discipline and reliance on government budgets. CDXS, by contrast, is a pre-profit platform company whose value depends on future adoption of enzymatic nucleic-acid manufacturing — a larger potential market but one still years from validated scale.
Momentum also diverges. AXON has shown recent technical stabilization and a product catalyst, but its one-year total return remains deeply negative. CDXS has posted a positive year-to-date return, yet its daily swings are wide and its price remains below key moving averages, reflecting choppy sentiment. On risk, AXON's beta (about 1.44) is moderate for a growth stock, while CDXS's beta near 2.55 signals substantially higher volatility. Investors comparing the two are effectively choosing between a de-rated, high-quality compounder and a high-variance, early-stage biotech story.
Tickeron AI Verdict
Based on observable factors — trend consistency, earnings stability, recurring revenue durability, and the depth of the contract backlog — Tickeron's AI would likely favor AXON over CDXS in the current environment. AXON's established profitability, 126% net revenue retention, and a recent product catalyst offer a more consistent and measurable fundamental profile, even after a sharp valuation reset. CDXS presents a credible long-term option but currently carries higher uncertainty tied to clinical and manufacturing milestones, ongoing losses, and share dilution. The assessment is probabilistic rather than definitive and reflects relative positioning at a point in time, not a prediction of future prices. One thing that stands out is how the AI highlights the stability gap between these two profiles.
Exploring AI Trading Tools for Deeper Insights
In my own research process, I often turn to Tickeron’s AI Trading Bots to test how systematic strategies might handle names like these across different market regimes. The platform offers a wide range of bots with varying styles and timeframes, which helps put the relative risks of AXON and CDXS into a broader, data-driven perspective without relying on a single approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CDXS sees its Stochastic Oscillator ascending out of oversold territory
On October 22, 2026, the Stochastic Oscillator for CDXS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 54 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CDXS just turned positive on October 23, 2026. Looking at past instances where CDXS's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Following a +6.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDXS advanced for three days, in 222 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CDXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDXS as a result. In 83 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CDXS entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.253) is normal, around the industry mean (3.037). P/E Ratio (-3.879) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (1.588) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. CDXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biocatalytic chemical processes
Industry Biotechnology
Advertisement